Skip to content

Released May 14, 2026, after the close

10-Q filed May 14, 2026, 44 days after period end · 0001683168-26-003909

Q1 2026 · 10-Q
Revenue—
Net Income-$5.63MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.24N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$5,705,956N/M
Operating Cash Flow-$5,017,327N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Net Income-$5.63M-$6.32M-$8.30M-$5.27M
EPS Diluted-$0.24-$0.32-$5.40—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR